Bactiguard wins tender for Stockholm
Bactiguard has won a tender for urinary catheters for the Stockholm county council, which enables healthcare providers in both primary and secondary care to purchase Bactiguards’ anti-infective urinary catheters. The contract is valid for 2 years and can be extended for another 2 years.
"The Stockholm county council is Sweden’s largest region and this is the largest tender for urinary catheters in the country. Several other regions have already included our products in their tenders, and the fact that Stockholm now also has taken this decision is an important milestone and acknowledgement of our work in Sweden” says Nina Nilsson, SVP Sales and Marketing at Bactiguard.
“It is also positive that the tender covers both primary and secondary care, as many long-term catheterized patients move between the two. This way, patients who have received Bactiguard catheters at the hospital, can continue using them after they have been discharged.”
The contract runs for two years from 6 November, 2017 and comprises BIP Foley Catheter in latex, BIP Foley Catheter Silicone and BIP Foley Tiemann.
In accordance with Swedish tender law, the Stockholm county council will execute the formal contract once the appeal period has expired, on 29 May 2017.
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com
Tags: